Patent Assignment
Reel/Frame 070521/0299
Release of Security Interest
Recorded: 2025-03-14
Pages: 31
Assignor
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Executed: 2025-03-14
Assignees
AZURITY PHARMACEUTICALS, INC.
841 WOBURN STREET, WILMINGTON, MASSACHUSETTS, 01887
SILVERGATE PHARMACEUTICALS, INC.
8 CABOT ROAD, SUITE 2000, WOBURN, MASSACHUSETTS, 01801
ARBOR PHARMACEUTICALS, LLC
SIX CONCOURSE PARKWAY, SUITE 1800, ATLANTA, GEORGIA, 30328
SLAYBACK PHARMA LIMITED LIABILITY COMPANY
301 CARNEGIE CENTER, SUITE 303, PRINCETON, NEW JERSEY, 08540
Covered Properties
(172)
Compositions and Kits for Compounding Pharmaceuticals
Patent:
6,708,822 →
Application:
09/707,783 →
Methods for Synthesis of Prodrugs from 1-Acyl-Alkyl Derivatives and Compositions Thereof
Orally Administered Dosage Forms of Gaba Analog Prodrugs Having Reduced Toxicity
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
A Transdermal Patch Composition for Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency
Composition For Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Crystalline Form of Y-Aminobutyric Acid Analog
Treating or Preventing Restless Legs Syndrome Using Prodrugs of Gaba Analogs
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Container and Method for the Preparation, Storage and Dispensing of Compounded Suppositories
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Methods for Synthesis of Prodrugs from 1-Acyl-Alkyl Derivatives and Compositions Thereof
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment-Resistant Strains of Head Lice
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Container and Kit for the Preparation, Storage and Dispensing of Compounded Suppositories
Crystalline Form of a (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrug and Methods of Use
Enantiomerically Resolving Acyloxyalkyl Thiocarbonates Used in Synthesizing Acyloxyalkyl Carbamate Prodrugs
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Methods of Synthesizing N-Hydroxysuccinimidyl Carbonates
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Sustained Release Oral Dosage Forms of an R-Baclofen Prodrug
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Container and Kit for the Preparation, Storage and Dispensing of Compounded Suppositories
Crystalline Form of a (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrug and Methods of Use
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Methods of Using Prodrugs of Pregabalin
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Enalapril Compositions
Patent:
8,568,747 →
Application:
13/670,355 →
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Enalapril Compositions
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
Application:
13/973,542 →
Publication:
US 2014/0056973
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application:
13/973,622 →
Publication:
US 2014/0056978
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Pharmaceutical Compositions of Dimethyl Fumarate
Sotalol Compositions and Uses of the Same
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Method of Making Monomethyl Fumarate
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Application:
14/449,513 →
Publication:
US 2015/0038499
Crystalline Forms of (N,N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Pharmaceutical Compositions of Fumaric Acid Esters
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Lisinopril Formulations
Patent:
9,463,183 →
Application:
14/934,752 →
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Container and Method for the Preparation, Storage and Dispensing of Compounded Suppositories
Enalapril Formulations
Patent:
9,669,008 →
Application:
15/081,603 →
Composition and Method for Vancomycin Oral Liquid
Crystalline Forms of (N,N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Lisinopril Formulations
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Enalapril Compositions
Lisinopril Formulations
Crystalline Forms of (N, N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Enalapril Formulations
Sotalol Compositions and Uses of the Same
Crystalline Forms of (N, N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Amlodipine Formulations
Composition and Method for Vancomycin Oral Liquid
Enalapril Formulations
Lisinopril Formulations
Enalapril Compositions
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Non-Aqueous Liquid Nimodipine Compositions
Topical Avermectin Formulations and Methods For Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
Application:
15/968,364 →
Publication:
US 2018/0242584
Pharmaceutical Compositions of Fumaric Acid Esters
Enalapril Formulations
Lisinopril Formulations
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Powder for Oral Suspension Containing Lamotrigine
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Patent:
10,456,354 →
Application:
16/176,866 →
Enalapril Formulations
Pharmaceutical Compositions of Dimethyl Fumarate
Enalapril Formulations
Sotalol Compositions and Uses of the Same
Lisinopril Formulations
Composition and Method for Proton Pump Inhibitor Suspension
Apparatus and Method for Filling Bulk Materials into a Container
Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof
Pharmaceutical Compositions of Testosterone
Pharmaceutical Compositions of Meloxicam
Amlodipine Formulations
Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
Application:
16/403,288 →
Publication:
US 2019/0256480
Non-Aqueous Liquid Nimodipine Compositions
Pharmaceutical Compositions of Posaconazole
Compositions and Kits for Omeprazole Suspension
Patent:
10,751,333 →
Application:
16/513,604 →
Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs Thereof
Application:
16/566,696 →
Publication:
US 2020/0000758
Composition and Method for Vancomycin Oral Liquid
Pharmaceutical Compositions of Lurasidone
Non-Aqueous Liquid Nimodipine Compositions
Crystalline Form of y-Aminobutyric Acid Analog
Application:
16/741,113 →
Publication:
US 2020/0283376
Pharmaceutical Compositions of Dimethyl Fumarate
Liquid Pharmaceutical Compositions of Baclofen for Oral Administration
Pharmaceutical Compositions of Lurasidone
Pharmaceutical Compositions of Nilotinib
Lisinopril Formulations
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Amlodipine Formulations
Enalapril Formulations
Composition and Method for Vancomycin Oral Liquid
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Application:
16/912,123 →
Publication:
US 2020/0323804
Amlodipine Formulations
Amlodipine Formulations
Composition and Method for Vancomycin Oral Liquid
Composition and Method for Vancomycin Oral Liquid
Pharmaceutical Compositions of Nilotinib
Powder for oral suspension containing lamotrigine
Application:
16/974,343 →
Publication:
US 2021/0401748
Composition and Method for Vancomycin Oral Liquid
Application:
16/988,387 →
Publication:
US 2021/0023002
Enalapril Formulations
Compositions and Kits for Omeprazole Suspension
Compositions and Kits for Omeprazole Suspension
Stable Pharmaceutical Compositions of Dihydroergotamine Mesylate
Sotalol Compositions and Uses of the Same
Amlodipine Formulations
Composition and Method for Vancomycin Oral Liquid
Application:
17/077,969 →
Publication:
US 2021/0038515
Suspensions and Diluents for Metronidazole and Baclofen
Enalapril Formulations
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application:
17/159,576 →
Publication:
US 2021/0145755
Composition and Method for Vancomycin Oral Liquid
Application:
17/165,754 →
Publication:
US 2021/0169799
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Application:
17/166,672 →
Publication:
US 2021/0228525
Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
Application:
17/188,422 →
Publication:
US 2021/0179573
Amlodipine Formulations
Lisinopril Formulations
Enalapril Formulations
Pharmaceutical Compositions of Tofacitinib for Oral Administration
Pharmaceutical Liquid Compositions of Meloxicam
Application:
17/368,367 →
Publication:
US 2022/0008337
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Stable Oral Suspensions of Baclofen
Pharmaceutical Compositions of Cabozantinib
Pharmaceutical Compositions of Testosterone
Pharmaceutical Liquid Compositions of Meloxicam
Application:
17/725,772 →
Publication:
US 2022/0249507
Stable Pharmaceutical Compositions of Succinylcholine Chloride
Application:
17/822,399 →
Publication:
US 2023/0086729
Stable Pharmaceutical Compositions of Succinylcholine Chloride
Pharmaceutical Compositions of Cabozantinib
Application:
17/824,518 →
Publication:
US 2022/0280500
Pharmaceutical Compositions of Mifepristone
Stable Pharmaceutical Compositions of Clonidine
Pharmaceutical Compositions of Cabozantinib
Application:
17/866,877 →
Publication:
US 2022/0362235
Stable Pharmaceutical Compositions of Bendamustine
Patent:
11,707,450 →
Application:
17/877,476 →
Pharmaceutical Compositions of Cabozantinib
Application:
17/885,105 →
Publication:
US 2022/0387418
Stable Oral Suspensions of Baclofen
Stable Pharmaceutical Compositions of Cyclophosphamide
Stable Liquid Compositions of Netupitant and Palonosetron
Modified-Release Dosage Forms of Ruxolitinib
Application:
18/075,150 →
Publication:
US 2023/0172863
Stable Oral Suspensions of Baclofen
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Pharmaceutical Compositions of Cabozantinib
Liquid Pharmaceutical Compositions of Baclofen for Oral Administration
Application:
18/114,502 →
Publication:
US 2024/0189229
Stable Pharmaceutical Compositions of Apixaban
Stable Oral Suspensions of Baclofen
Stable Pharmaceutical Compositions of Hydroxyurea
Application:
18/163,811 →
Publication:
US 2023/0301945
Stable Liquid Compositions of Glucagon
Pharmaceutical Compositions of Testosterone
Pharmaceutical Compositions of Cabozantinib
Stable Pharmaceutical Compositions of Bendamustine
Stable Pharmaceutical Compositions of Edaravone
Stable Pharmaceutical Compositions of Apixaban
Application:
18/357,295 →
Publication:
US 2024/0050416
Pharmaceutical Compositions of Tofacitinib for Oral Administration
Pharmaceutical Compositions of Nilotinib
Related Assignments
(20)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Agreement
Dec 16, 2014
From: CUTISPHARMA, INC.; RXEDESIGNEDMEDS, LLC; RXM THERAPEUTICS, LLC
To: SILICON VALLEY BANK
Reel/Frame 034648/0882 →
Assignment of Assignor's Interest
Jun 4, 2015
From: GALLOP, MARK A.; CUNDY, KENNETH C.; ZHOU, CINDY X.; YAO, FENMEI
To: XENOPORT, INC.
Reel/Frame 035788/0560 →
Assignment of Intellectual Property Security Agreement
Nov 15, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037112/0069 →
Security Interest
Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
Security Interest
Mar 21, 2018
From: CUTISPHARMA, INC.
To: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
Reel/Frame 045300/0385 →
Release of Security Interest
Mar 22, 2018
From: SILICON VALLEY BANK
To: CUTISPHARMA, INC.
Reel/Frame 045311/0168 →
Assignment of Assignor's Interest
Apr 20, 2018
From: ARBOR PHARMACEUTICALS, LLC
To: XENOPORT, INC.
Reel/Frame 046449/0306 →
Assignment of Assignor's Interest
Jul 25, 2018
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 046633/0753 →
Security Interest
May 17, 2019
From: CUTISPHARMA, INC.; SILVERGATE PHARMACEUTICALS, INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 049209/0272 →
Release of Security Interest
May 17, 2019
From: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
To: CUTISPHARMA, INC.
Reel/Frame 049212/0549 →
Assignment of Assignor's Interest
Oct 30, 2020
From: BRAUER, SCOTT; MOSHER, GEROLD L.
To: SILVERGATE PHARMACEUTICALS, INC.
Reel/Frame 054222/0945 →
Assignment of Assignor's Interest
Apr 2, 2021
From: SILVERGATE PHARMACEUTICALS, INC.
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 055805/0685 →
Security Interest
Apr 16, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055938/0859 →
Release of Security Interest
Aug 11, 2021
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 057142/0980 →
Security Interest
Sep 20, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057532/0424 →
Security Interest
Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
Release of Security Interest
Sep 20, 2021
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 057531/0403 →
Release of Security Interest
Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
Confirmatory Grant of Security Interest in United States Patents
Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
Termination and Release of Security Interest in Patents Recorded at Reel 049209, Frame 0272
Jun 24, 2025
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: CUTISPHARMA, INC. (N/K/A AZURITY PHARMACEUTICALS, INC.)
Reel/Frame 071704/0458 →